世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

治療抵抗性うつ病:パイプラインレビュー 2016年下半期

Treatment Resistant Depression - Pipeline Review, H2 2016

 

出版社 出版年月電子版価格 ページ数
Global Markets Direct
グローバルマーケッツダイレクト社
2016年10月US$2,000
シングルユーザライセンス
74

サマリー

Global Markets Directによる治療抵抗性うつ病のパイプラインレビューです。



Report Details

Treatment Resistant Depression - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides an overview of the Treatment Resistant Depression (Central Nervous System) pipeline landscape.

Treatment resistant depression (TRD) is an episode of major depressive disorder that does not respond to an antidepressant medication. Symptoms include difficulty concentrating, fatigue, insomnia, overeating or appetite loss and persistent aches or pains, headaches, cramps, or digestive problems. Treatment includes antidepressant from a different drug class, antipsychotic medication, electroconvulsive therapy (ECT) and vagus nerve stimulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Treatment Resistant Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Treatment Resistant Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 6 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Treatment Resistant Depression.

Treatment Resistant Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Treatment Resistant Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Treatment Resistant Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Treatment Resistant Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Treatment Resistant Depression (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Treatment Resistant Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Treatment Resistant Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

目次

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Treatment Resistant Depression Overview 7
Therapeutics Development 8
Pipeline Products for Treatment Resistant Depression - Overview 8
Pipeline Products for Treatment Resistant Depression - Comparative Analysis 9
Treatment Resistant Depression - Therapeutics under Development by Companies 10
Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes 11
Treatment Resistant Depression - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Treatment Resistant Depression - Products under Development by Companies 15
Treatment Resistant Depression - Products under Investigation by Universities/Institutes 16
Treatment Resistant Depression - Companies Involved in Therapeutics Development 17
Addex Therapeutics Ltd 17
Amorsa Therapeutics Inc. 18
Avanir Pharmaceuticals, Inc. 19
Axsome Therapeutics Inc 20
Biohaven Pharmaceutical Holding Company Limited 21
Eli Lilly and Company 22
Evotec AG 23
Johnson & Johnson 24
Otsuka Holdings Co., Ltd. 25
Relmada Therapeutics, Inc. 26
Reviva Pharmaceuticals Inc. 27
Sumitomo Dainippon Pharma Co., Ltd. 28
Takeda Pharmaceutical Company Limited 29
Treatment Resistant Depression - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 39
(bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(dextromethorphan + quinidine sulfate) - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
AMS-410 FA - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AMS-520 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AVP-786 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CX-157 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DSP-1200 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
esketamine hydrochloride - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
EVT-100 Series - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
LY-341495 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
REL-1017 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
riluzole - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
TAK-653 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
VU-0431316 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Treatment Resistant Depression - Dormant Projects 69
Treatment Resistant Depression - Discontinued Products 70
Treatment Resistant Depression - Product Development Milestones 71
Featured News & Press Releases 71
Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression 71
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 71
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る